First-line serplulimab plus chemotherapy versus chemotherapy in PD-L1-positive esophageal squamous-cell carcinoma: a cost-effectiveness analysis

Abstract Patients with PD-L1-positive esophageal squamous-cell carcinoma (ESCC) were significantly more likely to survive when treated with serplulimab plus cisplatin plus 5-fluorouracil (serplulimab-CF). At this point, it is unknown whether this expensive therapy is cost-effective. From the Chinese...

Descripción completa

Detalles Bibliográficos

Autores principales:	Xueyan Liang, Mingyu Meng, Shiran Qin, Xiaoyu Chen, Yan Li
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Nature Portfolio 2024-06-01
Colección:	Scientific Reports
Materias:	Serplulimab Esophageal squamous cell carcinoma Cost-effectiveness Chemotherapy Partitioned survival model
Acceso en línea:	https://doi.org/10.1038/s41598-024-65474-7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!